Enzalutamide (Xtandi) — Androgen Receptor Inhibitor for Castration-Resistant Prostate Cancer
July 16, 2026
Enzalutamide potently inhibits the androgen receptor (AR), remaining effective even when plasma testosterone is at castrate levels. A key option in advanced prostate cancer.
## AR Inhibition Mechanism
Enzalutamide (Xtandi) inhibits the androgen receptor more potently than older-generation Bicalutamide: blocking ligand binding, nuclear translocation and AR-dependent gene activation. It remains effective in castration-resistant prostate cancer (CRPC) — when plasma testosterone is below 50 ng/dL.
## Indications
Chemotherapy-treated and chemotherapy-naïve mCRPC, metastatic castration-sensitive prostate cancer (mCSPC) and high-risk non-metastatic CRPC (nmCRPC).
## In China
Prostate cancer incidence is rising in China. HYGEIA and GoBroad have experience treating CRPC with Enzalutamide, Abiraterone and next-generation ARSis. International patients should bring the latest PSA results, biopsy and imaging.
## Disclaimer
Information is for reference only. Uro-oncologists determine the protocol based on disease stage and test results.